loader
Please Wait
Applying Filters...

Annual Sales of Olmesartan Medoxomil reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 843Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Olmesartan

02 3Olmetec

03 1Olmetec / Olmetec Plus/ Sevikar / Sevikar Hct / Benicar/ Benicar Hct / Azor / Tribenzor

04 4Rezaltas

PharmaCompass

01

Brand Name : Rezaltas

Olmesartan Medoxomil

arrow
BioProcess International
Not Confirmed

Brand Name : Rezaltas

arrow
BioProcess International
Not Confirmed

Olmesartan Medoxomil

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 123

2019 Revenue in Millions : 137

Growth (%) : -11

blank

02

Brand Name : Olmesartan

Olmesartan

arrow
BioProcess International
Not Confirmed

Brand Name : Olmesartan

arrow
BioProcess International
Not Confirmed

Olmesartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 219

2019 Revenue in Millions : 214

Growth (%) : 2

blank

03

Brand Name : Olmesartan

Olmesartan

arrow
BioProcess International
Not Confirmed

Brand Name : Olmesartan

arrow
BioProcess International
Not Confirmed

Olmesartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 85

2019 Revenue in Millions : 96

Growth (%) : -11

blank

04

Brand Name : Olmetec

Olmesartan Medoxomil

arrow
BioProcess International
Not Confirmed

Brand Name : Olmetec

arrow
BioProcess International
Not Confirmed

Olmesartan Medoxomil

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 88

2019 Revenue in Millions : 113

Growth (%) : -22

blank

05

Brand Name : Rezaltas

Olmesartan Medoxomil

arrow
BioProcess International
Not Confirmed

Brand Name : Rezaltas

arrow
BioProcess International
Not Confirmed

Olmesartan Medoxomil

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 104

2020 Revenue in Millions : 122

Growth (%) : -8

blank

06

Brand Name : Olmesartan

Olmesartan

arrow
BioProcess International
Not Confirmed

Brand Name : Olmesartan

arrow
BioProcess International
Not Confirmed

Olmesartan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 171

2020 Revenue in Millions : 217

Growth (%) : -15

blank

07

Brand Name : Olmesartan

Olmesartan

arrow
BioProcess International
Not Confirmed

Brand Name : Olmesartan

arrow
BioProcess International
Not Confirmed

Olmesartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 155

2021 Revenue in Millions : 171

Growth (%) : -9

blank

08

Brand Name : Olmesartan

Olmesartan

arrow
BioProcess International
Not Confirmed

Brand Name : Olmesartan

arrow
BioProcess International
Not Confirmed

Olmesartan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 134

2022 Revenue in Millions : 155

Growth (%) : -2

blank

09

Brand Name : Olmetec

Olmesartan Medoxomil

arrow
BioProcess International
Not Confirmed

Brand Name : Olmetec

arrow
BioProcess International
Not Confirmed

Olmesartan Medoxomil

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 648

2016 Revenue in Millions : 536

Growth (%) : 21

blank

10

Brand Name : Olmetec / Olmetec Plus/ Sevikar / Sevikar Hct / Benicar/ Benicar Hct / Azor / Tribenzor

Olmesartan Medoxomil

arrow
BioProcess International
Not Confirmed

Brand Name : Olmetec / Olmetec Plus/ Sevikar / Sevikar Hct / Benicar/ Benicar Hct / Azor / Tribenzor

arrow
BioProcess International
Not Confirmed

Olmesartan Medoxomil

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 1,242

2017 Revenue in Millions : 608

Growth (%) : 104%

blank